返回 
加入收藏
醒脑静联合纳洛酮对肝性脑病患者相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 醒脑静联合纳洛酮对肝性脑病患者相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨醒脑静联合纳洛酮对肝性脑病患者相关指标的影响。方法：回顾性分析76例肝性脑病患者资料，按用药的不同分为对照组（40例）和观察组（36例）。在常规治疗基础上，对照组患者给予纳洛酮注射液1 mg ，加入10％葡萄糖溶液100 mL中，静脉滴注，每日2次；观察组患者在对照组治疗的基础上给予醒脑静注射液 20 mL，加入0.9％氯化钠注射液250 mL中，静脉滴注，每日1次。两组疗程均为2周。观察两组患者治疗前后长谷川痴呆量表（HDS）评分、简易智力状态检查量表（MMSE）评分、血氨、β-内啡肽、C-反应蛋白（CRP）、白细胞介素6（IL-6）、IL-10、肿瘤坏死因子α（TNF-α）水平及不良反应发生情况。结果：治疗后，两组患者HDS评分、MMSE评分均显著高于同组治疗前，且观察组显著高于对照组；两组患者血氨、β-内啡肽、IL-6、CRP和TNF-α水平均显著低于同组治疗前，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）；两组患者治疗前后IL-10水平比较，差异均无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，醒脑静联合纳洛酮可显著改善肝性脑病患者的认知功能，降低外周血神经毒性物质及炎症因子水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To explore the effects of xingnaojing combined with naloxone on related indexes of patients with hepatic encephalopathy. METHODS： In retrospective analysis， 76 patients with hepatic encephalopathy were divided into control group （40 cases） and observation group （36 cases） according to drug use. Based on routine treatment， control group was additionally given Naloxone injection 1 mg added into 10％ Glucose solution 100 mL intravenously twice a day. Observation group was additionally given Xingnaojing injection 20 mL added into 0.9％ Sodium chloride injection 250 mL intravenously once a day on the basis of control group. Treatment courses of 2 groups lasted for 2 weeks. HDS score， MMSE score， the levels of blood ammonia， β-endorphin， CRP， IL-6 and TNF-α， the occurrence of ADR were observed in 2 groups before and after treatment. RESULTS： After treatment， HDS score and MMSE score of 2 groups were significantly higher than before treatment， and the observation group was significantly higher than the control group； the levels of blood ammonia， β-endorphin， IL-6， CRP and TNF-α in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the level of IL-10 between 2 groups before and after treatment （P＞0.05）. There was no statistical significantly in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS：Based on routine treatment， Xingnaojing combined with naloxone can significantly improve cognitive function for patients with hepatic encephalopathy and reduce peripheral blood neurotoxin and inflammatory factor， moreover， do not increase the incidence of ADR. |
| 期刊： | 2017年第28卷第12期 |
| 作者： | 邓磊，李依 |
| AUTHORS： | DENG Lei，LI Yi |
| 关键字： | 肝性脑病；醒脑静；纳洛酮；认知功能；神经毒性物质；炎症因子 |
| KEYWORDS： | Hepatic encephalopathy； Xingnaojing； Naloxone； Cognitive function； Neurotoxin； Inflammation factor |
| 阅读数： | 291 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
